Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136695 · ClinicalTrials.gov registry record · Phase 2
Anastrozole Administration in Elderly Hypogonadal Men
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00136695: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00136695 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136695, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).
Interventions
- DRUG anastrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136695
The ClinicalTrials.gov registry entry for NCT00136695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anastrozole is the first listed.
NCT00136695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136695 about?
NCT00136695 is a clinical study titled "Anastrozole Administration in Elderly Hypogonadal Men". The purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).
What is the current status of trial NCT00136695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2004-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00136695?
The interventions under investigation include: anastrozole (DRUG).
Who is sponsoring clinical trial NCT00136695?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.